NCT00123773View on ClinicalTrials.gov

Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence

PHASE2CompletedINTERVENTIONAL

Enrollment

1,075

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions

SarcomaMultiple MyelomaTesticular NeoplasmsOvarian NeoplasmsKidney Neoplasms

Interventions

PROCEDURE

Positron Emission Tomography

Trial Locations (1)

T6G 1Z2

Cross Cancer Institute, Edmonton

All Listed Sponsors

collaborator

Cross Cancer Institute

OTHER

lead

AHS Cancer Control Alberta

OTHER

NCT00123773 - Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence | Biotech Hunter | Biotech Hunter